Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-02-26

Clinical Trial Update: Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) [Phase 3]

View source ↗

Summary

A Phase 3 study comparing Vidaza (azacitidine) with conventional care regimens in acute myeloid leukemia has completed. Results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VIDAZA (AZACITIDINE)

Snippet

Sponsor: Celgene | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2015-02-26